Further development of bithionol therapy as a treatment for amoebic gill disease in Atlantic salmon, Salmo salar L.

• Published in: Journal of Fish Diseases
• Main Authors: Florent, R L, Becker, J, Powell, M D
• Format: Article in Journal/Newspaper
• Language: English
• Published: Wiley 2009
• Subjects: Atlantic salmon; Salmo salar
• Online Access: http://dx.doi.org/10.1111/j.1365-2761.2008.01001.x; https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2761.2008.01001.x; https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2761.2008.01001.x

Abstract This study examined the efficacy of bithionol as a prophylactic or therapeutic oral treatment for Atlantic salmon (AS), Salmo salar , affected by amoebic gill disease (AGD). Furthermore, it explored the interaction of bithionol oral therapy with the current standard treatment (a freshwater bath for at least 3 h). The efficacy of three medicated feeds was determined in the trial by feeding AGD‐affected AS at 1% body weight (BW) day −1 either oil coated commercial feed (control) or prophylactic and therapeutic bithionol at 25 mg kg −1 feed. Feeding commenced 2 weeks prior to exposure to Neoparamoeba spp. at 300 cells L −1 and continued for 49 days post‐exposure (PE). Bithionol when fed as a 2‐week prophylactic or therapeutic treatment at 25 mg kg −1 feed delayed the onset of AGD pathology and reduced the percentage of gill filaments with lesions. Administration of a 3‐h freshwater bath at 28 days PE significantly reduced amoeba numbers to a similar level across all treatments; in contrast, gross gill score and percent lesioned filaments were reduced to different extents, the control having a significantly higher score than both bithionol treatments. Following the freshwater bath, clinical signs of AGD increased at a similar level across all treatments, albeit controls were significantly higher than the bithionol treatments immediately following freshwater treatment. This study demonstrated that bithionol at 25 mg kg −1 feed, when fed as a 2‐week prophylactic or a therapeutic treatment, delayed and reduced the intensity of AGD pathology and warrants further investigation as a treatment for AGD‐affected AS.